Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1653 participants.
Also called NCT02520180
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,653 participants
- Registry
-
NCT02520180
-
- Other papers using this trial's data
- 2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent
- Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark
- Registry status
- Completed
Technical summary
Registry record NCT02520180. Randomized; no masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2016-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Firehawk™ stent system
- Intervention (Device)
- Abbott Xience family Everolimus-Eluting Stent
- Lead sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Record details
- Record id
cardio:ct-nct02520180- Content hash
cf10b65ec525afc6c1489abd373030316b26c143c04b5ee8b00d301734b6dc21